About
Technology
Issues
FAQ
Links
Official Page
Dacomitinib (PF-00299804), An Irreversible Pan-Her Tyrosine Kinase Inhibitor (TKI), For First-Line Treatment of EGFR-Mutant or Her2-Mutant or -Amplified Lung Cancers
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.